Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Filing today

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Nov 07, 2023 11:46am

79 Views

Post# 35721612

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Filing today

Draining down inventories has no impact on Ebitda... It does reduce the cash outlay but no impact on Ebitda

SPCEO1 wrote: I did not read what he said that way. He was just pointing out that the new cash will not help them avoid potentially breaching the new covenants. I too am concerned about that. Not highly converned, but one has to consider every possibility with THTX unfortunately. I agree, as someone pointed out, that the head of sales insider purchases are encouraging that they will not likely breach that covenant soon. But THTX drained down inventories to produce the good Q3 adjusted EBITDA number and if there were an unexpected production issue (as has happened in the past) they could find themselves breaking these new covenants again. If this were to happen soon after good TH-1902 results were released, could Marathon seek to take over the assets knowing they cold maximize their return in that manner? Probably not, but I know PWIB has some experience with such lenders and I was hoping he might weigh in on if this was something we should be concerned about.
palinc2000 wrote:
Ir was said that they altready know that they wont be able to meet the Adjusted Ebitda requirement and I am responding to that.
As far as this could be a posdibility sometimes in the future .... of course it could

SPCEO1 wrote: If you read what was said you will see nothing like THTX already being in default was stated. But they have been a serial defaulter already so one should consider all possibilities even if they seem unlikely at the moment.
palinc2000 wrote:
So you think that there is a chance that they would be already in default on an amendment signed on October 13 2023?
Please stop this collective schizophrenia..

JayjayUSA12007 wrote: "I would like to suggest that you send them a letter outlining the question and what the solution to this possibility is? We can't just leave it to somebody on the forum and you are the best person to ask this question and get clarification."

I agree. Having cash after this secondary would not satisfy the EBITDA requirement. They need to provide shareholders with an approach to avoid breaching Marathon demand.
With these incompetent and unethical people, anything is possible...